MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21-Reference-Cited by-同舟云学术

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

Published:2019-08-14 Issue:505 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Vilgelm Anna E.¹²³^ORCID,Saleh Nabil¹²,Shattuck-Brandt Rebecca¹²^ORCID,Riemenschneider Kelsie⁴,Slesur Lauren²,Chen Sheau-Chiann⁵^ORCID,Johnson C. Andrew¹²^ORCID,Yang Jinming¹²,Blevins Ashlyn¹²^ORCID,Yan Chi¹²,Johnson Douglas B.⁶,Al-Rohil Rami N.⁷^ORCID,Halilovic Ensar⁸,Kauffmann Rondi M.⁹,Kelley Mark⁹,Ayers Gregory D.⁵,Richmond Ann¹²^ORCID

Affiliation:

1. Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, USA.

2. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

3. Department of Pathology, Ohio State University, Columbus, OH 43210, USA.

4. Department of Dermatology, University of Texas Southwestern, Medical Center, Dallas, TX 75390, USA.

5. Division of Cancer Biostatistics, Department of Biostatistics, Vanderbilt University Center for Quantitative Sciences, Nashville, TN 37232, USA.

6. Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

7. Department of Pathology, Duke University, Durham, NC 27708, USA.

8. Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.

9. Division of Surgical Oncology, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Abstract

CDK4/6 inhibition becomes effective in preclinical models of melanoma when combined with MDM2 antagonism.

Funder

National Institutes of Health

U.S. Department of Veterans Affairs

Breast Cancer Research Foundation

Harry J. Lloyd Charitable Trust

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference75 articles.

1. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

2. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

3. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

4. Treatment of NRAS-Mutant Melanoma

5. Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation;International Immunopharmacology;2024-12

2. Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling;Journal of Experimental & Clinical Cancer Research;2024-08-30

3. Advances in Melanoma: From Genetic Insights to Therapeutic Innovations;Biomedicines;2024-08-14

4. The role of palbociclib on the alterations in CDKN2, CCNE1, E2F3, MDM2 expressions as target genes of miR-141;PLOS ONE;2024-08-08

5. HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice;International Journal of Molecular Sciences;2024-07-08